Northern Trust Corp Purchases 13,115 Shares of Perspective Therapeutics, Inc. (NYSE:CATX)

Northern Trust Corp increased its position in shares of Perspective Therapeutics, Inc. (NYSE:CATX) by 2.8% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 487,273 shares of the company’s stock after buying an additional 13,115 shares during the period. Northern Trust Corp’s holdings in Perspective Therapeutics were worth $1,554,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of the company. Rhumbline Advisers raised its stake in Perspective Therapeutics by 4.5% during the fourth quarter. Rhumbline Advisers now owns 94,992 shares of the company’s stock worth $303,000 after buying an additional 4,075 shares during the last quarter. Bank of New York Mellon Corp raised its stake in Perspective Therapeutics by 3.4% during the fourth quarter. Bank of New York Mellon Corp now owns 143,469 shares of the company’s stock worth $458,000 after buying an additional 4,693 shares during the last quarter. JPMorgan Chase & Co. raised its stake in Perspective Therapeutics by 24.1% during the third quarter. JPMorgan Chase & Co. now owns 24,912 shares of the company’s stock worth $333,000 after buying an additional 4,844 shares during the last quarter. Nicholson Wealth Management Group LLC raised its stake in Perspective Therapeutics by 0.4% during the fourth quarter. Nicholson Wealth Management Group LLC now owns 1,609,283 shares of the company’s stock worth $5,134,000 after buying an additional 7,000 shares during the last quarter. Finally, Nebula Research & Development LLC raised its stake in Perspective Therapeutics by 47.2% during the fourth quarter. Nebula Research & Development LLC now owns 21,850 shares of the company’s stock worth $70,000 after buying an additional 7,007 shares during the last quarter. Institutional investors own 54.66% of the company’s stock.

Perspective Therapeutics Trading Up 0.4%

Shares of NYSE CATX opened at $2.40 on Wednesday. The company has a 50-day moving average price of $2.24 and a 200-day moving average price of $3.19. Perspective Therapeutics, Inc. has a 1 year low of $1.60 and a 1 year high of $16.55.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on CATX shares. Scotiabank started coverage on shares of Perspective Therapeutics in a research note on Friday, March 7th. They issued a “sector outperform” rating and a $15.00 price target for the company. Brookline Capital Management raised shares of Perspective Therapeutics to a “strong-buy” rating in a research note on Monday, March 10th. Wedbush reaffirmed an “outperform” rating and issued a $11.00 price target on shares of Perspective Therapeutics in a research note on Tuesday, May 13th. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price target on shares of Perspective Therapeutics in a research note on Monday, March 31st. Finally, Truist Financial decreased their price target on shares of Perspective Therapeutics from $10.00 to $8.00 and set a “buy” rating for the company in a research note on Wednesday, May 14th. One investment analyst has rated the stock with a hold rating, seven have given a buy rating and three have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Perspective Therapeutics presently has an average rating of “Buy” and an average price target of $12.50.

Insider Activity

In other news, CEO Johan M. Spoor purchased 22,026 shares of the business’s stock in a transaction that occurred on Friday, March 28th. The shares were acquired at an average cost of $2.24 per share, for a total transaction of $49,338.24. Following the completion of the acquisition, the chief executive officer now owns 59,383 shares in the company, valued at $133,017.92. This trade represents a 58.96% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Robert F. Williamson III purchased 38,145 shares of the business’s stock in a transaction that occurred on Monday, March 31st. The shares were purchased at an average price of $2.14 per share, for a total transaction of $81,630.30. Following the completion of the acquisition, the director now owns 108,982 shares of the company’s stock, valued at $233,221.48. The trade was a 53.85% increase in their position. The disclosure for this purchase can be found here. Insiders acquired 115,696 shares of company stock worth $256,344 over the last three months. 3.52% of the stock is currently owned by insiders.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.